Recombinant Rat Thrombomodulin Protein , His

Thrombomodulin (TM) is a multifunctional glycoprotein primarily expressed on the surface of endothelial cells, playing a crucial role in the regulation of coagulation and inflammation. Research into recombinant thrombomodulin (rTM) has gained momentum due to its therapeutic potential in various pathological conditions. TM acts as a cofactor for thrombin, converting it from a procoagulant enzyme into an anticoagulant that activates protein C, leading to the inactivation of factors Va and VIIIa and a subsequent reduction in thrombin generation. Beyond its anticoagulant properties, TM exhibits anti-inflammatory effects by modulating the endothelial cell response and inhibiting leukocyte adhesion, which is beneficial in diseases characterized by systemic inflammation and coagulopathy, such as sepsis and acute lung injury. The advent of recombinant DNA technology enables the production of rTM, offering advantages over traditional sources derived from human or animal tissues, including consistency, safety, and the ability to meet therapeutic demands. Recent studies have shown that rTM can improve survival rates in septic patients and reduce organ dysfunction, highlighting its promising role in critical care settings. Ongoing research aims to further elucidate the mechanistic pathways through which rTM exerts its protective effects and to evaluate its efficacy in various clinical populations. Consequently, rTM represents a novel therapeutic agent that could significantly alter the management of thrombotic and inflammatory disorders in modern medicine.